HOME >> BIOLOGY >> NEWS
UNC Center for Genome Sciences to inaugurate new seminar series with help of national experts

CHAPEL HILL -- The University of North Carolina at Chapel Hills new Center for Genome Sciences will kick off a seminar series on functional genomics, proteomics and bioinformatics Aug. 27 with a talk by Dr. Oliver Smithies, one of the universitys most distinguished scientists.

More than a dozen other national experts in those fields will follow during the 2001-2002 academic year. Smithies address is titled Mouse Solutions to Pharmacological Problems. He is excellence professor of pathology and laboratory medicine at the UNC School of Medicine. He also is developer of gene targeting, a renowned technique that allows scientists to disable genes in mice and breed successive generations of the animals to learn what role genes play in mammals, including humans.

Talks are free, and the public is encouraged to attend. All but the Oct. 1 presentation will be held on Mondays from noon to 1:30 p.m. in Room 136 of the Tate-Turner-Kuralt Building, located off Pittsboro Street. Genomics and proteomics are studies of information in genes and proteins, respectively, and bioinformatics is the science of handling and using biological data.

This is an exciting opportunity for the university community and the public to hear from some of the nations top scientists about the revolution in our current understanding of what genes and proteins do, said Dr. Harold L. Kohn. Kenan professor of medicinal chemistry at the school of pharmacy, Kohn co-chairs the new seminar series with Dr. Jeffrey L. Dangl, John N. Couch professor of biology.

The Human Genome Project is nearly complete, Kohn said. It has provided a wealth of sequence information leading to identification of all known genes. Similarly, rapid progress is being made to sequence the genetic material of known pathogens and organisms that affect life and well being.

The next challenge will be to provide meaning to this vast catalog of information, a challenge orders of magnitude more difficult than th
'"/>

Contact: David Williamson
David_Williamson@unc.edu
University of North Carolina at Chapel Hill
16-Aug-2001


Page: 1 2 3

Related biology news :

1. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways
2. Joslin Diabetes Center honors brothers living 70-plus years with type 1 diabetes
3. K-States National Agricultural Biosecurity Center receives $1.3 Million from Department of Defense
4. Joslin Diabetes Center adds first affiliate in California at Irvine Medical Center
5. NHGRI launches Centers for Excellence in Ethical, Legal, and Social Implications Research
6. NIGMS funds Center for Quantitative Biology
7. Joslin Diabetes Center launches research section on developmental and stem cell biology
8. Joslin Diabetes Center releases new low impact exercise video
9. Workforce achievements celebrated at NASA Marshall Center Awards ceremony
10. National Bioinformatics Resource Center to support infectious disease research
11. National Parkinson Foundation designates UNC as Center of Excellence

Post Your Comments:
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/26/2015)... 26, 2015 ATL Technology, LLC, a top provider ... in single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Jose, Costa Rica ). This acquisition will ... with ATL Technology,s existing facility in Costa ...
(Date:6/25/2015)... , June 25, 2015  Imagine a tool specifically ... a healthier, happier life. That,s exactly what USANA,s ... do. The cutting-edge, portable health program provides a personalized ... to help improve your lifestyle and nutrition. ... and gala Wednesday night, USANA,s THA was honored with ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
(Date:7/2/2015)... , ... July 02, 2015 , ... ... and manufacturing of surgical instruments in Orthopedics, announced today the acquisition of ... the world's largest provider of surgical instruments to the Spine Industry. The acquisition ...
(Date:7/1/2015)... , July 1, 2015   Decision Resources ... cited advantages of Otezla are its oral administration, ... as reported by surveyed rheumatologists. Otezla was the ... the treatment of active psoriatic arthritis in ... standard of care includes conventional oral treatments including ...
(Date:7/1/2015)... ALTO, Calif. , July 1, 2015 /PRNewswire/ ... focused on the development of groundbreaking drugs to ... (ALS), announced today that Robert G. Miller ... Center at Sutter Health,s California Pacific Medical Center ... The ALS Association for $1.5 million to help ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business ... to lower the barriers to innovation in life sciences R&D. The Pistoia Alliance President’s ... cash prizes of US$15,000 and a period of expert mentorship from a senior industry ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
Cached News: